Tumor-directed immune response

Tumor-directed immune response is a complex physiological process characterized by the host immune system's ability to recognize, infiltrate, and eliminate malignant cells (National Cancer Institute, 2024). This multi-step process, often referred to as the cancer-immunity cycle, involves the release of cancer cell antigens, antigen presentation by dendritic cells, priming and activation of T cells, and the subsequent trafficking and infiltration of these cells into the tumor microenvironment (Chen & Mellman, 2013, Immunity). In a healthy state, this response serves as a critical surveillance mechanism; however, tumors often evolve to evade this detection by exploiting inhibitory pathways such as the PD-1/PD-L1 or CTLA-4 checkpoints (Pardoll, 2012, Nature Reviews Cancer). Therapeutic strategies in oncology, including immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines, are specifically designed to restore or amplify this tumor-directed immune response (Waldman et al., 2020, Nature Reviews Immunology). Because this term describes a broad biological outcome involving diverse cellular populations and signaling cascades rather than a single druggable protein, it is classified as a therapeutic mechanism or biological phenomenon rather than a discrete molecular target (Ribas & Wolchok, 2018, Science).

Other names

Anti-tumor immunityTumor-specific immune responseHost anti-tumor immune responseCancer-directed immune responseCancer-immunity cycle

Induction or restoration of the host's adaptive and innate immune systems to identify and destroy tumor cells by blocking inhibitory signals or providing engineered immune effectors (Pardoll, 2012; Waldman et al., 2020).